Detalhe da pesquisa
1.
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
Lancet
; 401(10373): 281-293, 2023 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36566761
2.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol
; 21(3): 345-357, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32035020
3.
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
BJU Int
; 126(2): 292-299, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32336008
4.
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.
BMJ Open
; 13(8): e069176, 2023 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37550022
5.
The biology of antihormone failure in breast cancer.
Breast Cancer Res Treat
; 80 Suppl 1: S29-34; discussion S35, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14535532
6.
Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
Breast Cancer Res Treat
; 81(1): 81-93, 2003 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-14531500